Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Get Free Report) Director Frank Karbe bought 12,500 shares of the stock in a transaction dated Friday, December 13th. The stock was purchased at an average price of $7.93 per share, with a total value of $99,125.00. Following the purchase, the director now owns 57,000 shares in the company, valued at $452,010. This trade represents a 28.09 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Phathom Pharmaceuticals Stock Up 2.8 %
PHAT stock opened at $8.37 on Wednesday. The business has a 50 day moving average of $12.58 and a 200 day moving average of $13.16. The firm has a market cap of $572.32 million, a PE ratio of -1.47 and a beta of 0.56. Phathom Pharmaceuticals, Inc. has a twelve month low of $6.07 and a twelve month high of $19.71.
Analysts Set New Price Targets
Several equities analysts have commented on the company. HC Wainwright reissued a “buy” rating and set a $28.00 price objective on shares of Phathom Pharmaceuticals in a research report on Thursday, December 12th. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price target on shares of Phathom Pharmaceuticals in a research note on Wednesday, December 11th.
Institutional Investors Weigh In On Phathom Pharmaceuticals
A number of institutional investors have recently modified their holdings of the stock. Huntington National Bank boosted its stake in Phathom Pharmaceuticals by 62.2% in the 3rd quarter. Huntington National Bank now owns 1,471 shares of the company’s stock worth $27,000 after purchasing an additional 564 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Phathom Pharmaceuticals by 41.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,470 shares of the company’s stock worth $43,000 after buying an additional 722 shares during the last quarter. US Bancorp DE lifted its stake in shares of Phathom Pharmaceuticals by 28.6% in the third quarter. US Bancorp DE now owns 5,248 shares of the company’s stock worth $95,000 after buying an additional 1,166 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Phathom Pharmaceuticals by 10.6% in the second quarter. The Manufacturers Life Insurance Company now owns 13,941 shares of the company’s stock worth $144,000 after buying an additional 1,339 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Phathom Pharmaceuticals by 12.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 19,573 shares of the company’s stock valued at $208,000 after buying an additional 2,172 shares during the last quarter. 99.01% of the stock is owned by hedge funds and other institutional investors.
Phathom Pharmaceuticals Company Profile
Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
Featured Articles
- Five stocks we like better than Phathom Pharmaceuticals
- Most Volatile Stocks, What Investors Need to Know
- AppLovin Insiders Sell Shares: Stock Price Indicated Higher
- Are Penny Stocks a Good Fit for Your Portfolio?
- Broadcom’s Stellar Outlook Sparks Hopes for a Semi Sector Rally
- What is Insider Trading? What You Can Learn from Insider Trading
- Salesforce’s Clear Path to $400 and Beyond
Receive News & Ratings for Phathom Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phathom Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.